Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 4
2017 1
2018 2
2019 2
2020 6
2021 7
2022 3
2023 3
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for frangiamore r
Search for Fragiamore R instead (1 results)
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Bril V, et al. J Neurol. 2025 Mar 19;272(4):275. doi: 10.1007/s00415-025-12958-9. J Neurol. 2025. PMID: 40105996 Free PMC article. Clinical Trial.
Efgartigimod improves triple-negative myasthenia gravis.
Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C. Frangiamore R, et al. Neurol Sci. 2024 Mar;45(3):1307-1309. doi: 10.1007/s10072-023-07122-y. Epub 2023 Oct 24. Neurol Sci. 2024. PMID: 37875596 No abstract available.
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis: A New Mechanism of Action Beyond IgG Reduction.
Tarasco MC, Rinaldi E, Frangiamore R, Vanoli F, Berni A, Iacomino N, Canciello A, Andreetta F, Ciusani E, Bonanno S, Maggi L, Baggi F, Mantegazza R, Antozzi C, Cavalcante P. Tarasco MC, et al. Among authors: frangiamore r. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200455. doi: 10.1212/NXI.0000000000200455. Epub 2025 Jul 31. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 40743488 Free PMC article.
Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Mantegazza R, et al. Among authors: frangiamore r. Immunotargets Ther. 2020 Dec 15;9:317-331. doi: 10.2147/ITT.S261414. eCollection 2020. Immunotargets Ther. 2020. PMID: 33365280 Free PMC article. Review.
30 results